For men diagnosed with low-risk prostate cancer, active surveillance has long been recommended as a strategy to avoid or delay the side effects of surgery and radiation. Yet a growing body of evidence reveals that a substantial proportion of men who start surveillance eventually switch to definitive treatment—or are lost to follow-up—within just a few years. These dropout rates, which range from roughly 30% to 50% in large US registries and around 25% in Swedish cohorts by year three, have prompted concern among researchers that many men are being treated unnecessarily. The ideal dropout rate, many experts agree, should be below 20%.

Active Surveillance Dropout Rates Are Higher Than Expected

Active surveillance is not a passive approach. It involves regular PSA tests, digital rectal exams, and periodic prostate biopsies to monitor for progression. When followed strictly, it can safely defer treatment for years. But in practice, many men do not stay the course. Data from the multi-center Prostate Cancer Active Surveillance Study (PASS) and other US registries indicate that 30% to 50% of men receive definitive treatment within five years of enrollment. The reasons vary, but the pattern is consistent: surveillance is harder to maintain than many clinicians anticipate.

In Sweden, where national guidelines have promoted active surveillance since the early 2000s, dropout rates are somewhat lower but still notable. A 2023 analysis of the Swedish National Prostate Cancer Register found that roughly 25% of men on surveillance had switched to treatment by year three. Even in countries with centralized health systems and standardized protocols, a significant minority of men exit surveillance sooner than recommended.

Defining dropout is itself a matter of debate. Some studies count any receipt of definitive therapy—surgery, radiation, or focal therapy—as dropout, even if the decision was clinically appropriate. Others include men who are lost to follow-up, who may have sought care elsewhere or simply stopped coming. The heterogeneity makes cross-study comparisons difficult, but the overall trend is clear: surveillance is underutilized or poorly adhered to in many settings.

Experts argue that if surveillance is to fulfill its promise of reducing overtreatment, dropout rates need to fall. A consensus statement from the American Society of Clinical Oncology in 2024 suggested that programs achieving less than 20% dropout at five years should be the target. Most current programs fall short.

Why Men Leave Surveillance: Psychologic and System Failures

Anxiety about undetected progression is perhaps the most common reason men opt for treatment. Even with reassuring PSA levels and negative biopsies, the knowledge that a cancer is present—even a low-risk one—can be psychologically burdensome. Studies using validated instruments such as the Memorial Anxiety Scale for Prostate Cancer show that a subset of men experience clinically significant distress, and that distress correlates with higher dropout rates.

System-level factors also play a role. Surveillance protocols vary widely between practices. Some urologists recommend annual biopsies; others schedule them every two to three years. Some rely on PSA density and MRI findings to guide biopsy intervals; others do not. Without standardized follow-up, patients may receive mixed messages about when surveillance is still appropriate, eroding confidence in the strategy.

Urologists themselves may default to treatment when patients express hesitation. In fee-for-service settings, there is a financial incentive to perform procedures, though most clinicians would deny that this influences their recommendations. Nevertheless, research has documented that urologists who own their own radiation equipment are more likely to recommend treatment over surveillance. The conflict of interest is subtle but real.

Shared decision-making tools, which have been shown to improve knowledge and reduce decisional conflict, remain underused. A 2022 survey of US urology practices found that fewer than one in five routinely used a formal decision aid for men with low-risk prostate cancer. Without such tools, patients may not fully understand the trade-offs between immediate treatment and surveillance, leading to decisions driven by fear rather than evidence.

Overtreatment Harms Are Well Documented Yet Often Discounted

Radical prostatectomy, the most common surgical treatment, carries risks of urinary incontinence and erectile dysfunction. Rates vary by surgeon volume and technique, but even in the best hands, a significant minority of men experience lasting problems. A study in the New England Journal of Medicine reported that at five years after surgery, about 15% of men used pads for incontinence and nearly 60% reported erectile dysfunction severe enough to interfere with intercourse.

Radiation therapy, whether external beam or brachytherapy, carries its own set of long-term side effects. Bowel urgency, rectal bleeding, and bladder irritation are common, and can persist for years. A systematic review in JAMA Internal Medicine estimated that up to 30% of men who undergo radiation experience moderate to severe bowel or urinary symptoms at five years. These effects are often downplayed during initial counseling.

Androgen deprivation therapy (ADT), sometimes added to radiation for higher-risk disease, is associated with increased cardiovascular mortality, bone loss, and metabolic changes. A 2020 analysis of Medicare data found that men receiving ADT had a 20% higher risk of cardiovascular death compared with those who did not. For men with low-risk disease who might never have needed treatment, these harms are particularly hard to justify.

The number needed to treat to prevent one prostate cancer death is estimated to be between 30 and 40, meaning that for every man whose life is extended by treatment, dozens are treated unnecessarily. This ratio is worse than for many other cancers where screening and treatment are better targeted. Overtreatment is not a theoretical concern; it is a measurable public health problem.

Risk Stratification Tools Are Available but Inconsistently Applied

National Comprehensive Cancer Network (NCCN) guidelines have long recommended that men considering active surveillance undergo risk stratification using PSA density, Gleason grade group, and multiparametric MRI. The PI-RADS scoring system, which standardizes MRI interpretation, has been shown to improve selection for surveillance by identifying men with clinically significant lesions who might benefit from immediate treatment.

Genomic classifiers such as Decipher and Oncotype DX for prostate cancer add prognostic information beyond traditional clinical variables. These tests analyze gene expression in biopsy tissue and can stratify men into risk categories more precisely than Gleason score alone. A 2023 prospective study in European Urology found that use of a genomic classifier reclassified about 30% of men from low-risk to intermediate-risk, prompting a change in management.

Despite these tools, adoption varies widely. Academic centers and high-volume practices are more likely to use MRI and genomic testing routinely. Community practices, where the majority of men receive care, often lack access to MRI or have long wait times for biopsy. Even when tools are available, clinicians may not incorporate them into decision-making consistently. A 2024 survey of urologists found that only about half routinely ordered MRI before recommending surveillance.

The gap between evidence and practice means that many men who could safely avoid treatment are not identified, while others who might benefit from early treatment are placed on surveillance. Better dissemination of risk stratification tools, along with training in their interpretation, could reduce both overtreatment and undertreatment.

The Canary PASS Cohort Offers Lessons on Structured Surveillance

The Canary Prostate Cancer Active Surveillance Study (PASS) is one of the largest prospective cohorts of men on surveillance, with over 2,000 enrolled at multiple North American centers. Its protocol mandates PSA tests every six months and a surveillance biopsy at 12–24 months, then every two to three years thereafter. Biopsy compliance at five years has exceeded 85%, and dropout to treatment has been approximately 15%—well below the rates seen in registry studies.

What explains the difference? PASS centers are high-volume academic sites with dedicated research coordinators who track patients and remind them of appointments. Patients receive standardized education about the rationale for surveillance and the expected timeline. When progression is detected, it is typically grade reclassification on biopsy, which triggers a discussion about treatment—but the decision remains shared.

Importantly, PASS data show that the majority of men who remain on surveillance do not experience progression to metastatic disease or prostate cancer death. A 2025 analysis reported a 10-year metastasis-free survival of 98% among men who stayed on protocol. This suggests that a well-run surveillance program can be both safe and sustainable.

The PASS experience demonstrates that dropout is not inevitable. With structured follow-up, patient engagement, and clear protocols, adherence can be high. The challenge lies in scaling these practices to the broader healthcare system, where resources and infrastructure vary.

Policy and Payment Changes Could Shift Practice

Current Medicare reimbursement for active surveillance counseling is minimal. A typical office visit for surveillance check-in may be reimbursed at a fraction of the rate for a biopsy or a radiation planning session. This creates a perverse incentive: it pays better to treat than to watch. Several policy proposals aim to address this imbalance by bundling surveillance services or paying a monthly management fee.

Value-based payment models, such as those tested by the Center for Medicare and Medicaid Innovation, have shown promise in reducing unnecessary procedures. In some accountable care organizations, urologists receive a fixed payment per patient and are rewarded for avoiding low-value interventions. Preliminary data suggest these models are associated with higher rates of active surveillance and lower rates of definitive treatment for low-risk disease.

Some private insurers now require documentation of a surveillance plan before authorizing treatment for low-risk prostate cancer. This step, while administrative, forces a pause and a conversation. Professional societies including the American Urological Association have called for quality metrics tied to surveillance rates, such as the proportion of low-risk men on surveillance or the rate of biopsy compliance at one year.

None of these policies is a silver bullet. Payment reform alone will not address patient anxiety or clinician bias. But combined with better risk stratification and structured programs, they could move the needle. The goal is not to eliminate treatment for low-risk disease—some men will always need it—but to ensure that every treatment is a deliberate, well-informed choice rather than a default response to fear.

Lessons from International Comparisons

Dropout rates also vary by country, offering clues about which system features promote adherence. In the United Kingdom, the ProtecT trial—which randomized men to active surveillance, surgery, or radiation—reported that after 10 years, about 55% of men in the surveillance arm had received treatment, but many conversions were due to protocol-driven triggers rather than patient anxiety. The trial's structured follow-up and centralized coordination likely contributed.

In Finland, the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) observed that among screened men diagnosed with low-risk disease, approximately 70% chose surveillance initially, but dropout to treatment over 10 years was around 40%. The Finnish healthcare system's use of primary care coordination and patient navigators may explain higher retention compared to some US cohorts.

Canada offers a mixed picture. Population-based data from Ontario suggest that about 35% of men with low-risk prostate cancer receive treatment within three years of diagnosis, but rates vary substantially by region and urologist. Provinces with centralized cancer agencies and standardized protocols, such as British Columbia, tend to have lower treatment rates than those with more fragmented care.

These international examples highlight that system design matters. Countries that invest in coordinated follow-up, patient education, and clear guidelines achieve better adherence. The US, with its fragmented insurance landscape and variable practice patterns, faces particular challenges. Learning from successful models abroad could inform domestic policy.

What Clinicians and Patients Can Do Now

For clinicians, adopting a shared decision-making aid before finalizing the surveillance decision is a practical step. Tools such as the one developed by the Agency for Healthcare Research and Quality are freely available and have been shown to improve knowledge and reduce decisional conflict. Patients should be encouraged to bring a list of questions and to consider a second opinion at a high-volume center if their case is borderline.

Patients should also confirm that their urologist has access to multiparametric MRI and that a plan for regular PSA checks and biopsies is in writing. If surveillance is chosen, adherence to the schedule is critical. Missing a biopsy by a year or more can allow a potentially aggressive cancer to progress undetected. A 2023 study linked longer biopsy intervals to higher rates of grade reclassification at subsequent biopsy.

It is worth recognizing that dropout is not necessarily a failure. If a man develops anxiety that impairs his quality of life, or if a repeat biopsy shows grade progression, treatment may be the right choice. The key is that the decision to leave surveillance should be deliberate, informed, and made in consultation with the care team—not driven by fear or system gaps.

Ultimately, the evidence suggests that active surveillance is a safe and effective option for many men with low-risk prostate cancer, but only if it is implemented well. The high dropout rates seen in real-world practice are a signal that the healthcare system is not yet optimized to support this approach. Addressing the psychologic, structural, and financial barriers to adherence could reduce overtreatment and its associated harms.

This article is for informational purposes only and does not constitute medical advice. Patients should consult their healthcare provider before making any decisions about prostate cancer treatment or surveillance.